190
Participants
Start Date
March 22, 2010
Primary Completion Date
March 17, 2014
Study Completion Date
May 19, 2014
Blood collection
Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
GSK HIV vaccine 732462
No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Philadelphia
GSK Investigational Site, Philadelphia
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Annandale
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Móstoles, Madrid
GSK Investigational Site, Orlando
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Columbus
GSK Investigational Site, Nantes
GSK Investigational Site, Bochum
GSK Investigational Site, Essen
GSK Investigational Site, Valencia
GSK Investigational Site, Cologne
GSK Investigational Site, Omaha
GSK Investigational Site, Paris
GSK Investigational Site, Dallas
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Erlangen
GSK Investigational Site, Bobigny
GSK Investigational Site, Bakersfield
GSK Investigational Site, Créteil
GSK Investigational Site, Seattle
GSK Investigational Site, Camden
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY